These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22057727)

  • 21. Influenza virus resistance to antiviral agents: a plea for rational use.
    Poland GA; Jacobson RM; Ovsyannikova IG
    Clin Infect Dis; 2009 May; 48(9):1254-6. PubMed ID: 19323631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
    Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
    Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1.
    Maltezou HC; Drakoulis N; Siahanidou T; Karalis V; Zervaki E; Dotsikas Y; Loukas YL; Theodoridou M
    Pediatr Infect Dis J; 2012 May; 31(5):527-9. PubMed ID: 22209917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oseltamivir for the treatment of H1N1 influenza during pregnancy.
    Beigi RH; Pillai VC; Venkataramanan R; Caritis SN
    Clin Pharmacol Ther; 2015 Oct; 98(4):403-5. PubMed ID: 26108913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
    Dixit R; Khandaker G; Ilgoutz S; Rashid H; Booy R
    Infect Disord Drug Targets; 2013 Feb; 13(1):34-45. PubMed ID: 23675925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.
    Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M
    J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Foreword: Oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience.
    Nguyen-Van-Tam JS
    J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii3-ii4. PubMed ID: 20215133
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N; Ohashi Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2575-82. PubMed ID: 20368393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.
    Hurt AC; Deng YM; Ernest J; Caldwell N; Leang L; Iannello P; Komadina N; Shaw R; Smith D; Dwyer DE; Tramontana AR; Lin RT; Freeman K; Kelso A; Barr IG
    Euro Surveill; 2011 Jan; 16(3):. PubMed ID: 21262183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Etiotropic therapy of influenza: lessons from the last pandemic].
    Kolobukhina LV; Shchelkanov MIu; Merkulova LN; Bazarova MV; Burtseva EI; Samokhvalov EI; Al'khovskiĭ SV; Prilipov AG; Fediakina IT; Proshina ES; Aristova VA; Morozova TN; Sutochnikova OA; Ponomarenko RA; Malyshev NA; Maslov AM; Chuchalin AG
    Vestn Ross Akad Med Nauk; 2011; (5):35-40. PubMed ID: 21786595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages.
    Janies DA; Voronkin IO; Studer J; Hardman J; Alexandrov BB; Treseder TW; Valson C
    Int J Health Geogr; 2010 Feb; 9():13. PubMed ID: 20181276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.
    Kumaki Y; Day CW; Smee DF; Morrey JD; Barnard DL
    Antiviral Res; 2011 Nov; 92(2):329-40. PubMed ID: 21925541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010.
    Meijer A; Jonges M; Abbink F; Ang W; van Beek J; Beersma M; Bloembergen P; Boucher C; Claas E; Donker G; van Gageldonk-Lafeber R; Isken L; de Jong A; Kroes A; Leenders S; van der Lubben M; Mascini E; Niesters B; Oosterheert JJ; Osterhaus A; Riesmeijer R; Riezebos-Brilman A; Schutten M; Sebens F; Stelma F; Swaan C; Timen A; van 't Veen A; van der Vries E; te Wierik M; Koopmans M
    Antiviral Res; 2011 Oct; 92(1):81-9. PubMed ID: 21767571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards.
    Järhult JD; Muradrasoli S; Wahlgren J; Söderström H; Orozovic G; Gunnarsson G; Bröjer C; Latorre-Margalef N; Fick J; Grabic R; Lennerstrand J; Waldenström J; Lundkvist A; Olsen B
    PLoS One; 2011; 6(9):e24742. PubMed ID: 21931841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States.
    Graitcer SB; Gubareva L; Kamimoto L; Doshi S; Vandermeer M; Louie J; Waters C; Moore Z; Sleeman K; Okomo-Adhiambo M; Marshall SA; St George K; Pan CY; LaPlante JM; Klimov A; Fry AM
    Emerg Infect Dis; 2011 Feb; 17(2):255-7. PubMed ID: 21291599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses.
    Ciancio BC; Meerhoff TJ; Kramarz P; Bonmarin I; Borgen K; Boucher CA; Buchholz U; Buda S; Dijkstra F; Dudman S; Duwe S; Hauge SH; Hungnes O; Meijer A; Mossong J; Paget WJ; Phin N; van der Sande M; Schweiger B; Nicoll A
    Euro Surveill; 2009 Nov; 14(46):. PubMed ID: 19941797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro and in vivo efficacy of Ingavirin against strains of pandemic influenza virus A(H1N1/09)v].
    Shishkina LN; Nebol'sin VE; Kabanov AS; Skarnovich MO; Mazurkova NA; Sergeev AA; Serova OA; Stavskiĭ EA; Drozdov IG
    Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):93-6. PubMed ID: 21598625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential impact of neuraminidase inhibitor resistant influenza.
    Lackenby A; Thompson CI; Democratis J
    Curr Opin Infect Dis; 2008 Dec; 21(6):626-38. PubMed ID: 18978531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.